BioNTech and Genmab expand global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. First monospecific antibody candidate GEN1053BNT313 planned to enter clinical trials by the end of 2022. BioNTech will share costs and potential future profits on a 5050 basis.
💼 Business Developments:
✅ Partnership/Collaboration
❌ Acquisition Activity: Not reported
❌ Licensing Agreement: Not reported
✅ Regulatory Milestone
❌ Leadership Updates: Not reported
📞 Contact Information:
Media Contact: David Freundel, Director, Product CommunicationsT: +1 609 613 0504; E: dafr@genm
🌍 BioNTech SE (BNTX) - Form 6-K Filing
Filing Date: 2022-08-05
Accepted: 2022-08-05 06:49:07
Event Type: Clinical Trial Update
Event Details:
💼 Business Developments:
📞 Contact Information: